Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime
about
Decentralized control of human visceral leishmaniasis in endemic urban areas of Brazil: a literature reviewCutaneous Leishmaniasis Vaccination: A Matter of QualityDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Antigen-triggered interferon-γ and interleukin-10 pattern in cured mucosal leishmaniasis patients is shaped during the active phase of disease.Association between HLA genes and American cutaneous leishmaniasis in endemic regions of Southern BrazilLeishmaniases of the New World: current concepts and implications for future researchLocal or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.Plants used in the treatment of leishmanial ulcers due to Leishmania (Viannia) braziliensis in an endemic area of Bahia, Brazil.Epidemiological and clinical features of Leishmania (Viannia) braziliensis American cutaneous and mucocutaneous leishmaniasis in the State of Espírito Santo, Brazil.Mucosal leishmaniasis due to Leishmania (Viannia) braziliensis L(V)b in Três Braços, Bahia-Brazil.An unusual relapsing case of skin leishmaniasis.Cost-effectiveness of prevention strategies for American tegumentary leishmaniasis in Argentina.In Vitro Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on Leishmania infantum.Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis.Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.[Cutaneous leishmaniasis in the Metropolitan Region of Belo Horizonte: clinical, laboratorial, therapeutic and prognosis features (1989-1995)]Imported mucocutaneous leishmaniasis.Decrease in anti-Leishmania IgG3 and IgG1 after cutaneous leishmaniasis lesion healing is correlated with the time of clinical cure.The use of azythromycin and N-methyl glucamine for the treatment of cutaneous Leishmaniasis caused by Leishmania (Leishmania) amazonensis in C57BL6 mice.Molecular, cytological, and immunocytochemical study and kDNA sequencing of laryngeal Leishmania infantum infection.[A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use].Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment.Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
P2860
Q26739026-FB1A66D1-5122-4CC8-9D4A-8792B50B832BQ26752521-AD8C8120-CF64-4785-B8E4-277261FF66DBQ30275257-FA21A99E-FF23-43AF-B8E0-C5CF54C588A6Q34065388-5F7D5412-D072-40B3-9110-349C14E25B98Q34702872-C258AE06-E32E-4127-934E-ADF65B156124Q36640255-CD9E8CB1-4332-41DE-9A1F-445F9C0AC5C2Q38136837-E0C8208C-3101-41DB-90BE-B7FEB825F54CQ38156421-1CE4376F-03D2-4E0B-B926-05860DA192D0Q38511211-C5446E0F-2C2F-47FC-99EB-F911B69E62D0Q38563233-BF4F96B8-1A07-4A26-B611-228437ADF98FQ38998449-2A3BFBFA-2BF5-4E94-8466-6634CA71C5C3Q39217364-ED35EEFC-1EF6-4E11-8C94-621F4259602CQ39299827-ABDE3EDC-239A-486B-970E-581A519314B9Q39326575-0BFAE77B-5CF3-4CF5-B084-1035B3AB5F65Q39475712-C6C315B4-1FEF-497E-9905-1645F7679CFCQ40124194-F5EF21C7-592E-47EB-B914-5E9AF795989DQ40229581-103DA205-AFA0-4DAE-821E-31315E966AC3Q40380946-B3D01D94-ECF1-4457-852F-7DCE84608351Q43599586-45C95A2C-3858-4134-8A2D-5D8FE120CB55Q43704659-277E4634-0E9F-4F2A-9EFF-28886FDF00FAQ43865332-EBA5B7E7-3890-4E0D-A088-0BDBA825F5A2Q45979181-2FE065F9-49CC-4C2E-994A-FB3E0F03348EQ46228382-632DDCBB-E207-4B2D-A52B-0FD914C508FCQ46491616-7C49140C-1FBE-4F8B-BA64-A44C54D551E1Q46963413-7052FC31-A847-47C6-BA10-A1C225F3E54DQ53588405-654C941A-3324-42F8-88E6-BCC4AD9BDDCE
P2860
Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime
description
1990 nî lūn-bûn
@nan
1990 թուականին հրատարակուած գիտական յօդուած
@hyw
1990 թվականին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Long-term follow-up of patient ...... on and treated with Glucantime
@ast
Long-term follow-up of patient ...... on and treated with Glucantime
@en
Long-term follow-up of patient ...... on and treated with Glucantime
@nl
type
label
Long-term follow-up of patient ...... on and treated with Glucantime
@ast
Long-term follow-up of patient ...... on and treated with Glucantime
@en
Long-term follow-up of patient ...... on and treated with Glucantime
@nl
prefLabel
Long-term follow-up of patient ...... on and treated with Glucantime
@ast
Long-term follow-up of patient ...... on and treated with Glucantime
@en
Long-term follow-up of patient ...... on and treated with Glucantime
@nl
P2093
P3181
P1476
Long-term follow-up of patient ...... on and treated with Glucantime
@en
P2093
A C Barreto
E A Llanos-Cuentas
P D Marsden
W D Johnson
P304
P3181
P356
10.1016/0035-9203(90)90321-5
P407
P577
1990-01-01T00:00:00Z